METHODS: Patients with locally advanced or recurrence/metastatic malignant tumors of the nasal and paranasal sinuses were included. The SIADH was diagnosed according to the diagnostic criteria. The clinical characteristics of SIADH patients were retrospectively analyzed.
RESULTS: Six patients (6/188, 3.2%) met the diagnostic criteria of SIADH, including four olfactory neuroblastoma (4/26, 15.4%), one neuroendocrine carcinoma (1/9, 11.1%), and one squamous cell carcinoma (1/63, 1.6%). Five patients (83.3%) had severe hyponatremia; however, the hyponatremia could be improved by fluid restriction or tolvaptan. Three patients\' SIADH were recovered during the chemotherapy and the other three were recovered after the surgery.
CONCLUSIONS: The incidence of SIADH associated with nasal and paranasal malignant tumors is relatively more common in olfactory neuroblastoma and neuroendocrine carcinoma. The hyponatremia caused by SIADH may be corrected by fluid restriction or tolvaptan, and the SIADH may be recovered through anti-tumor therapy.
方法:纳入鼻腔和鼻旁窦局部晚期或复发/转移性恶性肿瘤患者。根据诊断标准诊断SIADH。回顾性分析SIADH患者的临床特点。
结果:6例患者(6/188,3.2%)符合SIADH的诊断标准,包括四个嗅觉神经母细胞瘤(4/26,15.4%),神经内分泌癌1例(1/9,11.1%),鳞状细胞癌1例(1/63,1.6%)。5例患者(83.3%)有严重低钠血症,然而,低钠血症可以通过限制液体或托伐普坦来改善。3例SIADH患者在化疗期间康复,另外3例在手术后康复。
结论:SIADH与鼻和鼻旁恶性肿瘤相关的发生率在嗅神经母细胞瘤和神经内分泌癌中相对更常见。由SIADH引起的低钠血症可以通过液体限制或托伐普坦来纠正,SIADH可以通过抗肿瘤治疗恢复。